同步顺铂放化疗对比单纯放疗治疗IIIB期鳞状宫颈癌的长期结局:随机对照试验
该分析基于既往III期随机对照试验的146例IIIB期鳞状宫颈癌患者(同步放化疗组72例,单纯放疗组74例),随访长达14年。长期随访显示,同步放化疗较单纯放疗显著改善无病生存(DFS)和总生存(OS)。基线KPS<90%和血红蛋白<10 mg/dL与更差的OS和DFS显著相关。
要点
- 同步顺铂放化疗较单纯放疗显著改善IIIB期鳞状宫颈癌的DFS和OS。
- 基线KPS<90%和血红蛋白<10 mg/dL是OS和DFS不良的独立预后因素。
- 长期随访支持同步放化疗作为IIIB期鳞状宫颈癌的标准治疗选择。
核心结论
- 对于IIIB期宫颈癌,同步放化疗较单纯放疗在DFS和OS上均带来显著获益。
研究设计与样本
- 对既往III期随机对照临床试验的长期随访分析,纳入146例IIIB期鳞状宫颈癌患者,同步放化疗组72例,单纯放疗组74例,随访长达14年。
主要发现
- 单纯放疗组较同步放化疗组OS显著更差(HR 1.88,95%CI 1.09-3.24),DFS也显著更差(HR 1.82,95%CI 1.07-3.08)。
- 基线KPS<90%的患者OS显著更差(HR 3.11,95%CI 1.78-5.43),DFS也显著更差(HR 2.83,95%CI 1.60-5.01)。
- 基线血红蛋白<10 mg/dL的患者OS显著更差(HR 4.32,95%CI 2.23-8.36),DFS也显著更差(HR 4.16,95%CI 2.17-7.95)。
临床怎么用
- 对于IIIB期鳞状宫颈癌,应优先考虑同步顺铂放化疗而非单纯放疗。
- 评估基线KPS和血红蛋白水平有助于识别预后较差、可能需要强化支持治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The present analysis determined the disease free survival (DFS) and overall survival (OS) at up to 14 years of follow-up in women who participated in our previous phase 3 randomized controlled clinical trial, in which women with stage IIIB squamous cervical cancer received either cisplatin plus RT or RT alone for treatment. The first study showed that the addition of cisplatin to RT offered a significant benefit in DFS, but not in OS. METHODS: The present analysis examined DFS and OS in 146 women from the original cohort (72 patients in the CRT arm and 74 patients in the RT-only arm) with follow-up of up to 14 years. RESULTS: Longer term follow-up showed that treatment with CRT offers a significant benefit in DFS and OS compared with treatment with RT only. Patients who received RT alone had significantly worse OS (HR, 1.88; 95% CI, 1.09-3.24) and DFS (HR, 1.82; 95% CI, 1.07-3.08) compared with patients who received CRT. The multivariate analyses also showed that the patients with baseline Karnofsky performance status (KPS) <90% showed significantly worse OS (HR, 3.11; 95% CI, 1.78-5.43), as did those with hemoglobin <10 mg/dL (HR, 4.32; 95% CI, 2.23-8.36). Patients with baseline KPS < 90% showed significantly worse DFS (HR, 2.83; 95% CI, 1.60-5.01), as did those with hemoglobin <10 mg/dL (HR, 4.16; 95% CI, 2.17-7.95). CONCLUSIONS: For stage IIIB cervical cancer, treatment with CRT offers a significant benefit in DFS and OS compared with treatment with RT only.
引用
- Fachini AMD, Zuliani AC, Sarian LO, et al. Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial. Gynecol Oncol. 2020. PMID: 33341239. doi:10.1016/j.ygyno.2020.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。